As of November 6, 2026, 8 holders' latest Schedule 13D or 13G filings report owning 5% or more of Nurix Therapeutics Inc. The largest reported stake is Redmile Group, LLC's, at 8.1%. 17 filings are on record since November 5, 2025 (Schedule 13G/A, August 14, 2026).
Sell to companies like Nurix Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 4,348,192 · Shared voting: 0 · Sole dispositive: 4,350,596 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-05
- · Reporting person: Perceptive Advisors LLC · Sole voting: 0 · Shared voting: 5,536,629 · Sole dispositive: 0 · Shared dispositive: 5,536,629 · SCHEDULE 13G, 2026-09-23
- · Reporting person: Redmile Group, LLC · Sole voting: 0 · Shared voting: 8,782,256 · Sole dispositive: 0 · Shared dispositive: 8,782,256 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Vestal Point Capital, LP · Sole voting: 0 · Shared voting: 8,050,000 · Sole dispositive: 0 · Shared dispositive: 8,050,000 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Deep Track Capital, LP · Sole voting: 0 · Shared voting: 7,736,455 · Sole dispositive: 0 · Shared dispositive: 7,736,455 · SCHEDULE 13G/A, 2026-08-14
Nurix Therapeutics Inc has 17 Schedule 13D or 13G filings on record since 2025-11-05. 8 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Redmile Group, LLC | 8.1% | 8,782,256 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Vestal Point Capital, LP | 7.8% | 8,050,000 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Deep Track Capital, LP | 7.45% | 7,736,455 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Baker Bros. Advisors LP | 7.2% | 7,527,996 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Rubric Capital Management LP | 6.96% | 7,227,778 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| T. Rowe Price Associates, Inc. | 5.3% | 5,436,587 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Perceptive Advisors LLC | 5.3% | 5,536,629 | SCHEDULE 13G, 2026-09-23 | 2026-09-16 |
| Vanguard Capital Management | 5.03% | 5,202,025 | SCHEDULE 13G, 2026-07-31 | 2026-06-30 |
| Commodore Capital LP | 4.9% | 3,780,055 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Fmr LLC | 4.2% | 4,350,596 | SCHEDULE 13G/A, 2026-11-05 | 2026-09-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Nurix Therapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Nurix Therapeutics Inc and the records around it.
Nurix Therapeutics Inc elsewhere on the record
Companies that share a holder
- Redmile Group, LLC also filed stake reports on 18 other companies: Electra Therapeutics, Inc. (Sep 2026), Neurogene Inc. (Aug 2026), Scholar Rock Holding Corporation (Aug 2026)
- Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), BeOne Medicines Ltd. (Sep 2026)
- Vestal Point Capital, LP also filed stake reports on 27 other companies: Alto Neuroscience, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Immunocore Holdings plc (Aug 2026)
Watch Nurix Therapeutics Inc
Get an email when Nurix Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Nurix Therapeutics Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Nurix Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Nurix Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Redmile Group, LLC | 0 | 8,782,256 | 0 | 8,782,256 | SCHEDULE 13G/A, 2026-08-14 |
| Jeremy C. Green | 0 | 8,782,256 | 0 | 8,782,256 | SCHEDULE 13G/A, 2026-08-14 |
| RedCo II Offshore SPV LLC | 0 | 3,712,546 | 0 | 3,712,546 | SCHEDULE 13G/A, 2026-08-14 |
| Vestal Point Capital, LP | 0 | 8,050,000 | 0 | 8,050,000 | SCHEDULE 13G/A, 2026-08-14 |
| Ryan Wilder | 0 | 8,050,000 | 0 | 8,050,000 | SCHEDULE 13G/A, 2026-08-14 |
| Deep Track Capital, LP | 0 | 7,736,455 | 0 | 7,736,455 | SCHEDULE 13G/A, 2026-08-14 |
| Deep Track Biotechnology Master Fund, Ltd. | 0 | 7,736,455 | 0 | 7,736,455 | SCHEDULE 13G/A, 2026-08-14 |
| David Kroin | 0 | 7,736,455 | 0 | 7,736,455 | SCHEDULE 13G/A, 2026-08-14 |
| Rubric Capital Management LP | 0 | 7,227,778 | 0 | 7,227,778 | SCHEDULE 13G, 2026-08-14 |
| David Rosen | 0 | 7,227,778 | 0 | 7,227,778 | SCHEDULE 13G, 2026-08-14 |
| T. Rowe Price Associates, Inc. | 5,250,628 | 0 | 5,436,587 | 0 | SCHEDULE 13G, 2026-08-14 |
| Perceptive Advisors LLC | 0 | 5,536,629 | 0 | 5,536,629 | SCHEDULE 13G, 2026-09-23 |
| Joseph Edelman | 0 | 5,536,629 | 0 | 5,536,629 | SCHEDULE 13G, 2026-09-23 |
| Perceptive Life Sciences Master Fund, Ltd. | 0 | 5,536,629 | 0 | 5,536,629 | SCHEDULE 13G, 2026-09-23 |
| Vanguard Capital Management | 706,496 | 0 | 5,202,025 | 0 | SCHEDULE 13G, 2026-07-31 |
| Fmr LLC | 4,348,192 | 0 | 4,350,596 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 4,350,596 | 0 | SCHEDULE 13G/A, 2026-11-05 |
The latest filing identifies Nurix Therapeutics Inc by CUSIP 67080M103 and gives its principal executive office as 1600 SIERRA POINT PKWY, BRISBANE, CA 94005 (SCHEDULE 13G/A, 2026-11-05).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-05 | Fmr LLC | 11.5% | SCHEDULE 13G/A |
| 2025-11-07 | Fmr LLC | 4.1% | SCHEDULE 13G/A |
| 2025-11-14 | Commodore Capital LP | 4.9% | SCHEDULE 13G/A |
| 2026-02-17 | Baker Bros. Advisors LP | 7.2% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-24 | Redmile Group, LLC | 9.9% | SCHEDULE 13G/A |
| 2026-05-06 | Fmr LLC | 5.4% | SCHEDULE 13G |
| 2026-05-15 | Vestal Point Capital, LP | 6.3% | SCHEDULE 13G |
| 2026-05-15 | Deep Track Capital, LP | 6.17% | SCHEDULE 13G/A |
| 2026-07-31 | Vanguard Capital Management | 5.03% | SCHEDULE 13G |
| 2026-08-14 | T. Rowe Price Associates, Inc. | 5.3% | SCHEDULE 13G |
| 2026-08-14 | Vestal Point Capital, LP | 7.8% | SCHEDULE 13G/A |
| 2026-08-14 | Rubric Capital Management LP | 6.96% | SCHEDULE 13G |
| 2026-08-14 | Redmile Group, LLC | 8.1% | SCHEDULE 13G/A |
| 2026-08-14 | Deep Track Capital, LP | 7.45% | SCHEDULE 13G/A |
| 2026-09-23 | Perceptive Advisors LLC | 5.3% | SCHEDULE 13G |
| 2026-11-05 | Fmr LLC | 4.2% | SCHEDULE 13G/A |
Questions about who owns Nurix Therapeutics Inc
Who owns Nurix Therapeutics Inc?
On this page, 8 holders' latest ownership filings report 5% or more of Nurix Therapeutics Inc: Redmile Group, LLC (8.1%, Schedule 13G/A, filed 2026-08-14), Vestal Point Capital, LP (7.8%, Schedule 13G/A, filed 2026-08-14), Deep Track Capital, LP (7.45%, Schedule 13G/A, filed 2026-08-14), Baker Bros. Advisors LP (7.2%, Schedule 13G/A, filed 2026-02-17) and Rubric Capital Management LP (6.96%, Schedule 13G, filed 2026-08-14); 3 more are listed above.
Who are the largest shareholders of Nurix Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Nurix Therapeutics Inc on this page are Redmile Group, LLC (8.1%), Vestal Point Capital, LP (7.8%) and Deep Track Capital, LP (7.45%).
When did Redmile Group, LLC buy into Nurix Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from Redmile Group, LLC on this page is the Schedule 13G/A, filed 2026-04-24, reporting 9.9%; its latest, Schedule 13G/A filed 2026-08-14, reports 8.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 17 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Nurix Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.